Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approvedBy |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:India gptkb:South_Korea gptkb:United_Kingdom gptkb:United_States |
| gptkbp:category |
immunologic adjuvant
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 Phase 3 |
| gptkbp:composition |
saponin-based adjuvant
|
| gptkbp:contains |
gptkb:Quillaja_saponaria_saponins
cholesterol phospholipids |
| gptkbp:developedBy |
gptkb:Novavax
|
| gptkbp:form |
nanoparticle
|
| https://www.w3.org/2000/01/rdf-schema#label |
Matrix-M adjuvant
|
| gptkbp:improves |
humoral immunity
cellular immunity |
| gptkbp:introducedIn |
2020
|
| gptkbp:mechanismOfAction |
enhances antigen presentation
stimulates immune response |
| gptkbp:patent |
gptkb:Novavax
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:sideEffect |
fever
fatigue headache muscle pain injection site pain |
| gptkbp:storage |
2-8°C
|
| gptkbp:usedIn |
gptkb:NVX-CoV2373
influenza vaccines malaria vaccines Ebola vaccines |
| gptkbp:bfsParent |
gptkb:Novavax_COVID-19_vaccine
|
| gptkbp:bfsLayer |
5
|